Navigation Links
Cause of effectiveness discovered for a cirrhosis treatment useful in 40 percent of patients
Date:2/27/2008

This release is available in Spanish.

Scientists of the Center for Applied Medical Research (CIMA) of the University of Navarra have discovered the molecular mechanism responsible for the effectiveness of an existing treatment for primary biliary cirrhosis, which combines two substances in order to produce an effect that does not result from either substance separately. The discovery involved the role played by the AE2 protein when the patient is treated with a combination of ursodeoxycholic acid (UDCA) together with glucocorticoids. The research results were recently published in The Journal of Clinical Investigation.

The origin of primary biliary cirrhosis (PBC)-which mostly affects middle-aged women-is still not understood. This pathology is associated with autoimmune phenomena, damage to the biliary vessels of the liver, and a reduction in the production of bile.

In Spain more than 1,000 cases are diagnosed each year, and the total number of patients worldwide is greater than 15,000. Dr. Juan Francisco Medina, Director of the Laboratory of Molecular Genetics of the CIMA, explains that in the present day the diagnosis of this disease, which is generally detected early, permits treatment with UDCA, which is effective in over half of the patients. However, nearly 40% of PBC patients do not respond satisfactorily to monotherapy with UDCA. Therefore, we looked for a combined treatment, and discovered that the combination of UDCA with glucocorticoids was a promising treatment for this group of patients. Those who suffer from this type of cirrhosis have a deficit of AE2, which is the protein for the secretion of bicarbonate in the bile.

The possibility of more cures with fewer transplants

The originality of this recently-published research article consists in relating, for the first time, the combined treatment with UDCA and glucocorticoids with a greater quantity of bicarbonate in the bile, and an improvement of the production of bile by the liver. Specifically, experiments in animal models and cell cultures demonstrate that only the combined treatment with UDCA and glucocorticoids increases the genetic expression of the human protein AE2 in the liver.

Based on available data, Dr. Medina considers that it is advisable to use combined treatment in those cases which present a poor response to monotherapy with UDCA. He proposes the use of a corticoid such as budesonida, which has fewer side effects than cortisone and prednisone. If, for fear of side effects, we allow the disease to progress, it is very probable that the only treatment will be a transplant. On the other hand, if this treatment option is confirmed as successful, it could reduce the number of transplants required in order to save the lives of patients.


'/>"/>

Contact: Oihane Lakar
oihane@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related medicine news :

1. Drug for cluster headaches may cause heart problems
2. Study Points to Cause of Vioxx Heart Risk
3. Damp, Moldy Homes May Cause Depression
4. Constipations Many Causes and Cures
5. High Co-Pays Cause Seniors to Go Without Meds
6. 13 percent of women stop taking breast cancer drug because of side effects, U-M study finds
7. Vocal cord dysfunction may be caused by work
8. Study finds drug spending caps cause some seniors to quit taking key medicines
9. Medicare Spending Caps Cause Seniors to Stop Meds
10. Gene Mutations May Cause Rare Neonatal Diabetes
11. Patent Expiries of Proscar and Flomax/Harnal Will Cause a Significant Decline in Near-Term Sales of Benign Prostatic Hyperplasia Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... ... open for the 31st annual AIDS Walk Boston & 5K Run , which will ... event regularly draws thousands of participants, making it AIDS Action Committee’s largest annual fundraiser. The ... USA Track & Field Association. , The AIDS Walk & 5K Run will begin ...
(Date:5/3/2016)... ... May 03, 2016 , ... Cosmetic surgeon Dr. Mark Youssef first ... incorporating the injectable filler into his menu of services to give his patients as ... a year later, he’s still improving his approach to ensure he stays at the ...
(Date:5/3/2016)... ... May 03, 2016 , ... University of the People, the ... of its Associates and Bachelor's degrees in Health Studies. Leading figures are heading ... Torsten N. Wiesel; Chairman and CEO of Fortune 500® company Henry Schein, Stanley ...
(Date:5/3/2016)... ... , ... Nationally recognized personal injury law firm Monge & Associates is honoring Moms ... who wants one for their Mother or any other mother figure. , According to law ... Monge goes on to say, “we are choosing to do this by giving free ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... announces Benefits Alliance Insurance Services as the latest addition to its elite stable ... comprised of Partners Wayne Blasman, David Styles, and Paul Vincent. The Firm is ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
(Date:4/28/2016)... April 28, 2016  The blood testing market in ... according to Kalorama Information and The Freedonia Group in ... nucleic acid testing.  The healthcare research firm said that ... developing blood collection stations and in improving testing at ... Information,s report, Blood Testing Market in China ...
Breaking Medicine Technology: